iShares Global Healthcare ETF (IXJ) Valuation
IXJ valuation today
Holdings combined · company data as of Oct 26, 2026- P/E (TTM)
- 37.4 trailing earnings
- Forward P/E
- 17.3 analyst estimates
- Price / sales
- 1.68
- Price / book
- 5.09
- EV / EBITDA
- 16.8
- Earnings yield
- 2.68% inverse of P/E
- Dividend yield
- 1.52% of the holdings
- Return on equity
- 13.6% combined
- Net margin
- 4.5% combined
- Beta
- 0.54 weighted, vs S&P 500
IXJ valuation vs other stock ETFs
| ETF | P/E | Fwd P/E | P/S | P/B | Div. yield | ROE | Net margin | Loss-makers |
|---|---|---|---|---|---|---|---|---|
| IXJ | 37.4 | 17.3 | 1.68 | 5.09 | 1.52% | 13.6% | 4.5% | 5.6% |
| SPY | 25.9 | 19.9 | 3.67 | 5.47 | 1.08% | 21.1% | 14.2% | 1.9% |
| QQQ | 34.2 | 23.4 | 5.93 | 9.27 | 0.58% | 27.1% | 17.4% | 6.9% |
| DIA | 20.9 | 18.4 | 3.16 | 5.52 | 1.55% | 26.4% | 15.1% | 0.0% |
| VTI | 28.2 | 19.4 | 3.31 | 5.00 | 1.07% | 17.7% | 11.8% | 4.6% |
| IWM | n/m | 13.9 | 1.25 | 2.03 | 1.38% | −1.7% | −1.0% | 28.1% |
Same method for every fund. n/m = not meaningful (combined trailing earnings below zero or close to it). Loss-makers = weight of holdings with negative trailing earnings.
IXJ valuation by sector
| Sector | Weight | P/E | Fwd P/E | P/S | P/B | Div. yield | ROE |
|---|---|---|---|---|---|---|---|
| Healthcare | 99.0% | 37.4 | 17.3 | 1.68 | 5.09 | 1.52% | 13.6% |
IXJ earnings yield vs bond yields
Earnings yield = earnings ÷ price (1 ÷ P/E). The gap to bond yields is a rough gauge of the extra return stocks are priced to deliver.
How IXJ weight splits by P/E
Share of the covered weight in companies with a trailing P/E in each range.
IXJ largest holdings: valuation
| Symbol | Company | Weight | P/E | Fwd P/E | P/S | Div. yield | Share of earnings |
|---|---|---|---|---|---|---|---|
| LLY | Eli Lilly and Company | 10.83% | 42.2 | 24.4 | 14.1 | 0.55% | 13.16% |
| JNJ | Johnson & Johnson | 6.70% | 38.8 | 21.0 | 6.2 | 2.10% | 8.86% |
| ABBV | AbbVie Inc. | 5.40% | 80.6 | 16.4 | 7.8 | 2.42% | 3.43% |
| UNH | UnitedHealth Group Incorporated | 4.38% | 25.8 | 16.6 | 0.8 | 2.31% | 8.69% |
| MRK | Merck & Co., Inc. | 4.19% | 115.8 | 15.3 | 5.4 | 2.33% | 1.86% |
| ROP | Roche Holding AG | 3.85% | — | — | — | — | — |
| NOVN | Novartis AG | 3.15% | — | — | — | — | — |
| AZN | AstraZeneca PLC | 3.05% | — | — | — | — | — |
| TMO | Thermo Fisher Scientific Inc. | 2.91% | 37.1 | 24.2 | 5.5 | 0.27% | 4.02% |
| AMGN | Amgen Inc. | 2.70% | 26.9 | 16.7 | 6.1 | 2.33% | 5.15% |
| GILD | Gilead Sciences, Inc. | 2.18% | — | 15.6 | 6.4 | 2.10% | −1.90% |
| PFE | Pfizer Inc. | 2.08% | 38.9 | 9.7 | 2.6 | 5.81% | 2.74% |
| ABT | Abbott Laboratories | 1.95% | 33.8 | 17.1 | 3.9 | 2.40% | 2.95% |
| ISRG | Intuitive Surgical, Inc. | 1.74% | 48.9 | 33.3 | 13.7 | — | 1.82% |
| DHR | Danaher Corporation | 1.62% | 40.8 | 23.8 | 6.4 | 0.70% | 2.03% |
| VRTX | Vertex Pharmaceuticals Incorporated | 1.56% | 28.9 | 24.1 | 10.1 | — | 2.76% |
| BMY | Bristol-Myers Squibb Company | 1.47% | 13.2 | 9.4 | 2.5 | 4.22% | 5.73% |
| NOVO-B | Novo Nordisk A/S | 1.45% | — | — | — | — | — |
| CVS | CVS Health Corporation | 1.44% | 24.3 | 10.7 | 0.3 | 2.88% | 3.04% |
| MCK | McKesson Corporation | 1.36% | 26.9 | 19.7 | 0.3 | 0.37% | 2.60% |
| MDT | Medtronic plc | 1.34% | 23.3 | 14.9 | 3.2 | 3.04% | 2.96% |
| GSK | GSK plc | 1.24% | — | — | — | — | — |
| SYK | Stryker Corporation | 1.18% | 30.5 | 16.5 | 4.4 | 1.19% | 1.97% |
| ELV | Elevance Health Inc. | 1.08% | 19.0 | 13.7 | 0.5 | 1.61% | 2.92% |
| SAN | Sanofi SA | 1.02% | — | — | — | — | — |
Share of earnings = the holding's part of the fund's combined trailing profit. Green: earns more than its weight; orange: less. Symbol links go to each company's key metrics.
About IXJ valuation
Adding up its 60 holdings with company data, IXJ trades at 37.4 times trailing earnings and 17.3 times analysts' forward estimates, with a price-to-book ratio of 5.09 and a dividend yield of 1.52%. Its earnings yield of 2.68% is 2.65 percentage points below the 5.33% yield to maturity of the U.S. bond market (AGG).
The ten largest holdings are 47.2% of the fund and earn 49.0% of its combined profit. Companies that lost money over the past year are 5.6% of the covered weight.
How these figures are calculated. Each ratio treats the fund as one company: the earnings, sales and book value of every holding are added up in proportion to its weight and divided into the fund's price. In practice that is a weighted harmonic mean, so a single stock with a very high P/E cannot distort the result, and loss-making companies reduce the fund's earnings instead of being dropped. Covers 73.6% of the fund's weight (U.S.-listed stocks with company data); company figures as of October 26, 2026.
Related: IXJ chart, IXJ performance, IXJ holdings, IXJ dividends.
IXJ valuation FAQ
What is the P/E ratio of IXJ?
Based on its holdings, IXJ has a trailing P/E of 37.4 and a forward P/E of 17.3 (earnings of all covered holdings combined in proportion to their weights, as of October 26, 2026).
What is the earnings yield of IXJ?
The trailing earnings yield is 2.68% (1 ÷ P/E) and the forward earnings yield 5.78%. For comparison the U.S. bond market (AGG) yields 5.33% to maturity and T-bills about 3.91%.
Is IXJ more expensive than the S&P 500?
IXJ trades at 37.4 times trailing earnings versus 25.9 for the S&P 500 (SPY); on forward estimates the figures are 17.3 and 19.9.
What is the price-to-book ratio of IXJ?
The holdings of IXJ trade at 5.09 times book value, with a combined return on equity of 13.6%.